Takeda's QDENGA Becomes the First Dengue Vaccine Approved in India

A Landmark Milestone in India's Fight Against Dengue

India has approved Takeda Pharmaceutical's QDENGA, making it the first dengue vaccine to receive regulatory approval in the country. The approval marks a significant advancement in India's efforts to reduce the burden of dengue, a mosquito-borne viral disease that continues to affect millions of people worldwide every year.

Developed by the Japanese pharmaceutical company Takeda, QDENGA is designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine is approved for use in children and adults aged 4 to 60 years.

Why This Approval Matters

Dengue is one of the world's fastest-growing mosquito-borne diseases. According to the World Health Organization (WHO), 2024 recorded approximately 14.4 million dengue cases and over 11,200 deaths globally.

In India alone, the WHO reported approximately:

• 232,425 confirmed dengue cases
• 233 dengue-related deaths

Over the last two decades, reported dengue cases in India have increased by nearly 11 times, highlighting the growing public health challenge and the need for effective preventive measures.

About QDENGA

QDENGA is a live-attenuated tetravalent dengue vaccine developed to protect against all four dengue virus serotypes.

Key Features

• ✅ First dengue vaccine approved in India.
• ✅ Provides protection against all four dengue virus serotypes.
• ✅ Approved for individuals 4 to 60 years of age.
• ✅ Can be administered regardless of previous dengue infection.
• ✅ No pre-vaccination blood test is required, making vaccination more convenient.
• ✅ Administered as two doses of 0.5 mL, with the second dose given three months after the first.

Clinical Trial Results

QDENGA has demonstrated strong clinical performance in global Phase III clinical trials.

Reported Efficacy

• 80.2% efficacy against laboratory-confirmed dengue infection one year after the second dose.
• 90.4% efficacy in preventing dengue-related hospitalizations 18 months after vaccination.

These results indicate that the vaccine can significantly reduce the risk of severe disease and hospitalization among vaccinated individuals.

Global Approval

Before receiving approval in India, QDENGA had already been approved in more than 43 countries, reflecting its growing global acceptance and use in dengue prevention programs.

Manufacturing in India

To strengthen vaccine availability and expand manufacturing capacity, Takeda India partnered with Biological E. Ltd. in 2024. This collaboration aims to support local production and improve long-term access to the vaccine across India.

How QDENGA Differs from Dengvaxia

QDENGA offers an important advantage over Sanofi's Dengvaxia.

Unlike Dengvaxia, which is recommended only for individuals with a previous dengue infection and requires pre-vaccination testing, QDENGA can be administered irrespective of prior dengue exposure. This simplifies vaccination and makes it suitable for a broader population.

Expert Perspective

Medical experts believe QDENGA has the potential to substantially reduce severe dengue cases and hospital admissions.

However, vaccination alone is not expected to eliminate dengue outbreaks. Effective mosquito control measures—including eliminating stagnant water, using mosquito repellents, maintaining sanitation, and community awareness—remain essential components of dengue prevention.

The Future of Dengue Prevention in India

The approval of QDENGA represents a major milestone in India's public health landscape. As dengue cases continue to rise, vaccination, combined with vector-control strategies and public awareness, can play a vital role in reducing disease burden and improving community health outcomes.

Indian vaccine manufacturers are also advancing their own dengue vaccine programs. Indian Immunologicals Limited (IIL) is currently preparing to begin mid-stage clinical trials for its dengue vaccine candidate, reflecting India's continued commitment to strengthening dengue prevention.

Key Highlights